ANIXA BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ANIXA BIOSCIENCES, INC. (ANIX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $7.04 per share for the 9-month period ending 2018-07-31, per its 10-Q filed 2019-09-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2019-09-06
- ANIXA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-01-31 was $3.63.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month |
|---|---|---|
| 2018-07-31 | $7.04 10-Q · filed 2019-09-06 | |
| 2018-01-31 | $3.63 10-Q · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |